Stock ALCLS CELLECTIS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Cellectis S.A. Stock

Equities

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:29 2024-04-19 am EDT 		After market 12:05:42 pm
2.39 EUR +1.06% Intraday chart for Cellectis S.A. 2.365 -1.05%
05:11pm European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT
Apr. 16 European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT

Financials

Sales 2023 * 21.51M 22.92M Sales 2024 * 27.32M 29.11M Capitalization 170M 181M
Net income 2023 * -69M -73.53M Net income 2024 * -69M -73.53M EV / Sales 2023 * 4.42 x
Net cash position 2023 * 74.53M 79.43M Net cash position 2024 * 18.69M 19.92M EV / Sales 2024 * 5.53 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 234
Yield 2023 *
-
Yield 2024 *
-
Free-Float 100%
More Fundamentals * Assessed data

Chart Cellectis S.A.

Dynamic Chart

Latest news about Cellectis S.A.

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5% MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
More news

Latest transcript on Cellectis S.A.

Logo Cellectis S.A.
Cellectis S.A., Q3 2023 Earnings Call, Nov 07, 2023
More transcripts

Analyst Recommendations on Cellectis S.A.

European Earnings, Rate-hike Predictions Push French Stocks to Red MT
Citigroup Adjusts Cellectis Price Target to $16 From $24, Maintains Buy Rating MT
Oppenheimer Adjusts Cellectis Price Target to $13 From $16, Maintains Outperform Rating MT
Goldman Sachs Adjusts Cellectis' Price Target to $2 from $3, Keeps Sell Rating MT
Baird Upgrades Cellectis to Outperform From Neutral MT
More recommendations

Press releases Cellectis S.A.

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs GL
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting GL
Cellectis S A : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social PU
Cellectis S A : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social PU
Acute Lymphocytic Leukemia Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 AQ
More press releases

News in other languages on Cellectis S.A.

C'est grave, docteur Powell ?
En Direct des Marchés : Publicis, Airbus, Société Générale, Vertex, Givaudan, UBS, KKR, Catana...
Cellectis publie une nouvelle approche d'édition intronique pour le traitement des maladies métaboliques congénitales par des cellules souches hématopoïétiques modifiées
On s'occupe comme on peut
En Direct des Marchés : EsssilorLuxottica, Bouygues, Atos, BioMérieux, UBS, Eli Lilly, L'Occitane...
More news

Quotes and Performance

1 day+1.06%
1 week-5.16%
Current month-3.94%
1 month+7.85%
3 months-2.21%
6 months+99.17%
Current year-13.53%
More quotes

Highs and lows

1 week
2.27
Extreme 2.27
2.47
1 month
2.13
Extreme 2.126
2.74
Current year
2.13
Extreme 2.126
2.88
1 year
0.89
Extreme 0.888
3.44
3 years
0.89
Extreme 0.888
17.03
5 years
0.89
Extreme 0.888
28.45
10 years
0.89
Extreme 0.888
41.95
More quotes

Managers and Directors - Cellectis S.A.

Managers TitleAgeSince
David Sourdive FOU
 Founder 57 99-12-19
André Choulika FOU
 Founder 59 99-12-19
Bing C. Wang DFI
 Director of Finance/CFO 47 22-02-09
Members of the board TitleAgeSince
Jean-Pierre Garnier CHM
 Chairman 75 20-11-04
André Choulika FOU
 Founder 59 99-12-19
David Sourdive FOU
 Founder 57 99-12-19
More insiders

Quotes

Date Price Change Volume
24-04-19 2.39 +1.06% 43 278
24-04-18 2.365 +0.85% 26,617
24-04-17 2.345 -0.64% 40,901
24-04-16 2.36 -0.42% 115,732
24-04-15 2.37 -5.95% 219,003

Real-time Euronext Paris, April 19, 2024 at 11:35 am EDT

More quotes

Company Profile

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.
Sector
Biotechnology & Medical Research
Calendar
2024-04-24 - The CRISPR MEDiCiNE Conference
More about the company

Income Statement Evolution

More financial data

Ratings for Cellectis S.A.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CELLECTIS S.A. Stock Cellectis S.A.
-13.53% 181M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.68% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+42.15% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+3.17% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+1.87% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.68% 18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.67% 11.68B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+21.18% 11.6B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.59% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALCLS Stock